The impact of cyclooxygenase inhibitor use on urinary prostaglandin metabolites in preterm infants
Background: There is limited evidence on the association between the clinical course of patent ductus arteriosus (PDA) and prostaglandin (PG) metabolites. This study aimed to determine the influence of PDA treatment on urinary PG metabolite excretion in very-low-birth-weight (VLBW) infants. Methods:...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2024-03-01
|
| Series: | Pediatrics and Neonatology |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S1875957223001328 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849703240881405952 |
|---|---|
| author | Natsuki Ohkawa Hiromichi Shoji Naho Ikeda Yayoi Murano Toshiaki Okuno Masato Kantake Takehiko Yokomizo Toshiaki Shimizu |
| author_facet | Natsuki Ohkawa Hiromichi Shoji Naho Ikeda Yayoi Murano Toshiaki Okuno Masato Kantake Takehiko Yokomizo Toshiaki Shimizu |
| author_sort | Natsuki Ohkawa |
| collection | DOAJ |
| description | Background: There is limited evidence on the association between the clinical course of patent ductus arteriosus (PDA) and prostaglandin (PG) metabolites. This study aimed to determine the influence of PDA treatment on urinary PG metabolite excretion in very-low-birth-weight (VLBW) infants. Methods: Urine samples were collected from 25 VLBW infants at 1, 3, and 7 days of age. Infants were separated into two groups: a PDA-treated group that received a cyclooxygenase-2 (COX) inhibitor (n = 12) and a control group that did not receive a COX inhibitor during the first 7 days after birth (n = 13). Urinary PG metabolite tetranor prostaglandin E2 metabolite (t-PGEM) and tetranor prostaglandin D2 metabolite (t-PGDM) levels were analyzed using liquid chromatography–tandem mass spectrometry. Results: Urinary t-PGEM excretion levels were not significantly different between the groups at 1, 3, and 7 days of age. Urinary t-PGDM excretion levels at 1 day of age were higher in PDA-treated infants than in control infants (median [interquartile range]: 5.5 [2.6, 12.2] versus 2.1 [1.0, 3.9] ng/mg creatinine; p = 0.017); however, among PDA-treated infants, the levels were significantly lower at 3 and 7 days than at 1 day of age (5.5 [2.6, 12.2] versus 3.4 [1.7, 4.5] and 4.0 [1.7, 5.3] ng/mg creatinine, respectively; p < 0.05). The urinary t-PGDM excretion level in the control group did not significantly differ among the time points. Conclusion: PDA and COX inhibitor administration affected PG metabolism in VLBW infants. Our results indicated that urinary t-PGDM excretion was significantly associated with PDA-treatment in preterm infants. |
| format | Article |
| id | doaj-art-146b288bbee440dcb3d3e1d7a7629b1a |
| institution | DOAJ |
| issn | 1875-9572 |
| language | English |
| publishDate | 2024-03-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Pediatrics and Neonatology |
| spelling | doaj-art-146b288bbee440dcb3d3e1d7a7629b1a2025-08-20T03:17:22ZengElsevierPediatrics and Neonatology1875-95722024-03-0165212312610.1016/j.pedneo.2023.08.002The impact of cyclooxygenase inhibitor use on urinary prostaglandin metabolites in preterm infantsNatsuki Ohkawa0Hiromichi Shoji1Naho Ikeda2Yayoi Murano3Toshiaki Okuno4Masato Kantake5Takehiko Yokomizo6Toshiaki Shimizu7Department of Neonatology, Juntendo University Shizuoka Hospital, 1129 Nagaoka, Izunokuni-shi, Shizuoka, 410-2295, Japan; Corresponding author.Department of Neonatology, Juntendo University Shizuoka Hospital, 1129 Nagaoka, Izunokuni-shi, Shizuoka, 410-2295, Japan; Department of Pediatrics, Juntendo University Faculty of Medicine, 2-1-1 Hongo, Bunkyo-ku, Tokyo 113-8421, JapanDepartment of Neonatology, Juntendo University Shizuoka Hospital, 1129 Nagaoka, Izunokuni-shi, Shizuoka, 410-2295, JapanDepartment of Pediatrics, Juntendo University Faculty of Medicine, 2-1-1 Hongo, Bunkyo-ku, Tokyo 113-8421, JapanDepartment of Biochemistry, Juntendo University Faculty of Medicine, 2-1-1 Hongo, Bunkyo-koi, Tokyo 113-8421, JapanDepartment of Neonatology, Juntendo University Shizuoka Hospital, 1129 Nagaoka, Izunokuni-shi, Shizuoka, 410-2295, JapanDepartment of Biochemistry, Juntendo University Faculty of Medicine, 2-1-1 Hongo, Bunkyo-koi, Tokyo 113-8421, JapanDepartment of Pediatrics, Juntendo University Faculty of Medicine, 2-1-1 Hongo, Bunkyo-ku, Tokyo 113-8421, JapanBackground: There is limited evidence on the association between the clinical course of patent ductus arteriosus (PDA) and prostaglandin (PG) metabolites. This study aimed to determine the influence of PDA treatment on urinary PG metabolite excretion in very-low-birth-weight (VLBW) infants. Methods: Urine samples were collected from 25 VLBW infants at 1, 3, and 7 days of age. Infants were separated into two groups: a PDA-treated group that received a cyclooxygenase-2 (COX) inhibitor (n = 12) and a control group that did not receive a COX inhibitor during the first 7 days after birth (n = 13). Urinary PG metabolite tetranor prostaglandin E2 metabolite (t-PGEM) and tetranor prostaglandin D2 metabolite (t-PGDM) levels were analyzed using liquid chromatography–tandem mass spectrometry. Results: Urinary t-PGEM excretion levels were not significantly different between the groups at 1, 3, and 7 days of age. Urinary t-PGDM excretion levels at 1 day of age were higher in PDA-treated infants than in control infants (median [interquartile range]: 5.5 [2.6, 12.2] versus 2.1 [1.0, 3.9] ng/mg creatinine; p = 0.017); however, among PDA-treated infants, the levels were significantly lower at 3 and 7 days than at 1 day of age (5.5 [2.6, 12.2] versus 3.4 [1.7, 4.5] and 4.0 [1.7, 5.3] ng/mg creatinine, respectively; p < 0.05). The urinary t-PGDM excretion level in the control group did not significantly differ among the time points. Conclusion: PDA and COX inhibitor administration affected PG metabolism in VLBW infants. Our results indicated that urinary t-PGDM excretion was significantly associated with PDA-treatment in preterm infants.http://www.sciencedirect.com/science/article/pii/S1875957223001328cyclooxygenase-2 inhibitorductus arteriosusinfantpreterm infantprostaglandins |
| spellingShingle | Natsuki Ohkawa Hiromichi Shoji Naho Ikeda Yayoi Murano Toshiaki Okuno Masato Kantake Takehiko Yokomizo Toshiaki Shimizu The impact of cyclooxygenase inhibitor use on urinary prostaglandin metabolites in preterm infants Pediatrics and Neonatology cyclooxygenase-2 inhibitor ductus arteriosus infant preterm infant prostaglandins |
| title | The impact of cyclooxygenase inhibitor use on urinary prostaglandin metabolites in preterm infants |
| title_full | The impact of cyclooxygenase inhibitor use on urinary prostaglandin metabolites in preterm infants |
| title_fullStr | The impact of cyclooxygenase inhibitor use on urinary prostaglandin metabolites in preterm infants |
| title_full_unstemmed | The impact of cyclooxygenase inhibitor use on urinary prostaglandin metabolites in preterm infants |
| title_short | The impact of cyclooxygenase inhibitor use on urinary prostaglandin metabolites in preterm infants |
| title_sort | impact of cyclooxygenase inhibitor use on urinary prostaglandin metabolites in preterm infants |
| topic | cyclooxygenase-2 inhibitor ductus arteriosus infant preterm infant prostaglandins |
| url | http://www.sciencedirect.com/science/article/pii/S1875957223001328 |
| work_keys_str_mv | AT natsukiohkawa theimpactofcyclooxygenaseinhibitoruseonurinaryprostaglandinmetabolitesinpreterminfants AT hiromichishoji theimpactofcyclooxygenaseinhibitoruseonurinaryprostaglandinmetabolitesinpreterminfants AT nahoikeda theimpactofcyclooxygenaseinhibitoruseonurinaryprostaglandinmetabolitesinpreterminfants AT yayoimurano theimpactofcyclooxygenaseinhibitoruseonurinaryprostaglandinmetabolitesinpreterminfants AT toshiakiokuno theimpactofcyclooxygenaseinhibitoruseonurinaryprostaglandinmetabolitesinpreterminfants AT masatokantake theimpactofcyclooxygenaseinhibitoruseonurinaryprostaglandinmetabolitesinpreterminfants AT takehikoyokomizo theimpactofcyclooxygenaseinhibitoruseonurinaryprostaglandinmetabolitesinpreterminfants AT toshiakishimizu theimpactofcyclooxygenaseinhibitoruseonurinaryprostaglandinmetabolitesinpreterminfants AT natsukiohkawa impactofcyclooxygenaseinhibitoruseonurinaryprostaglandinmetabolitesinpreterminfants AT hiromichishoji impactofcyclooxygenaseinhibitoruseonurinaryprostaglandinmetabolitesinpreterminfants AT nahoikeda impactofcyclooxygenaseinhibitoruseonurinaryprostaglandinmetabolitesinpreterminfants AT yayoimurano impactofcyclooxygenaseinhibitoruseonurinaryprostaglandinmetabolitesinpreterminfants AT toshiakiokuno impactofcyclooxygenaseinhibitoruseonurinaryprostaglandinmetabolitesinpreterminfants AT masatokantake impactofcyclooxygenaseinhibitoruseonurinaryprostaglandinmetabolitesinpreterminfants AT takehikoyokomizo impactofcyclooxygenaseinhibitoruseonurinaryprostaglandinmetabolitesinpreterminfants AT toshiakishimizu impactofcyclooxygenaseinhibitoruseonurinaryprostaglandinmetabolitesinpreterminfants |